Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class ITerminatedD-0008-2022

Drug recall · October 6, 2021

Ruzurgi recall

Why: Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.

Class I: a reasonable chance the product could cause serious harm or death.

The recall

Product

Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.

Lots / codes

Lot #: 18038, 18039, Exp 03/2023; 18079, Exp 05/2023

Quantity
2,324 bottles
Company
Jacobus Pharmaceutical Company Inc., Plainsboro, NJ
Distribution
Product was distributed within the USA and Canada. Control # 18038, was distributed to Canada only.
Initiated
September 9, 2021 · Voluntary: Firm initiated
Classified
October 8, 2021
Reported
October 6, 2021
Ended
February 18, 2022
How notified
Letter

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.